GlassScriptPhysician profile
Jordan A Barr
NPI 1003495508
$6,503.60
in general payments reported to CMS, 2019-2025
55 companies · $2,690 in 2025
The $2,690 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,580 · 2024: $2,234 · 2025: $2,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,411 · Education: $93.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,410.51 |
| Education | $93.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $621.04 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $528.73 | 2023-2025 | |
| Gilead Sciences, INC. | $388.74 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $383.65 | 2023-2025 | Darzalex, Talvey, Erleada |
| Glaxosmithkline, LLC. | $346.06 | 2023-2025 | Ojjaara, Jemperli, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $301.01 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astrazeneca Pharmaceuticals LP | $280.24 | 2023-2025 | Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $279.65 | 2023-2025 | Enhertu, Datroway |
| Pfizer INC. | $270.31 | 2023-2025 | |
| Stemline Therapeutics INC. | $257.05 | 2023-2025 | Orserdu |
| Genentech USA, INC. | $214.48 | 2023-2025 | Alecensa, Rozlytrek, Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $182.66 | 2023-2025 | |
| Abbvie INC. | $140.14 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $117.45 | 2023-2025 | Orgovyx |
| Genzyme Corporation | $110.77 | 2023-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $107.91 | 2023-2025 | Bavencio, Tepmetko |
| Jazz Pharmaceuticals INC. | $106.34 | 2024-2025 | |
| Celgene Corporation | $104.68 | 2023-2025 | Reblozyl, Opdualag |
| Exelixis INC. | $98.53 | 2023-2024 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.14 | 2023-2025 | Gilotrif |
| Eisai INC. | $95.74 | 2023-2025 | |
| Sobi, INC | $92.40 | 2024-2025 | |
| Array Biopharma INC | $80.26 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Incyte Corporation | $79.94 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| Adc Therapeutics America, INC. | $76.39 | 2024-2025 | |
| Genmab U.S., INC. | $76.28 | 2023-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $73.09 | 2023-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $72.99 | 2023-2024 | Ultomiris |
| Seagen INC. | $70.61 | 2023 | Adcetris, Tivdak, Padcev |
| Regeneron Healthcare Solutions, INC. | $66.61 | 2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $63.38 | 2024-2025 | |
| Telix Pharmaceuticals | $62.64 | 2024-2025 | Illuccix |
| Blueprint Medicines Corporation | $57.92 | 2023-2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $57.38 | 2023-2025 | Qinlock, Romvimza |
| Mirati Therapeutics, INC. | $55.60 | 2023-2024 | Krazati |
| Azurity Pharmaceuticals, INC. | $38.03 | 2025 | Danziten |
| Spectrum Pharmaceuticals INC. | $37.29 | 2024-2025 | Rolvedon |
| Geron Corporation | $37.07 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $35.74 | 2023-2024 | Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $35.01 | 2025 | Yescarta |
| Kyowa Kirin, INC. | $34.48 | 2023-2024 | Poteligeo |
| Agios Pharmaceuticals, INC. | $31.39 | 2024-2025 | Pyrukynd |
| Cycle Pharmaceuticals INC | $26.20 | 2025 | Phyrago |
| Dendreon Pharmaceuticals LLC | $21.04 | 2025 | Provenge |
| Avyxa Pharma, LLC | $20.44 | 2025 | |
| Acrotech Biopharma INC. | $20.42 | 2024 | Beleodaq |
| Syndax Pharmaceuticals, INC. | $19.88 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $19.88 | 2024 | Sancuso |
| Servier Pharmaceuticals LLC | $18.73 | 2024 | |
| Beigene USA, INC. | $17.90 | 2025 | Tevimbra |
| Myriad Genetic Laboratories, INC. | $16.24 | 2024 | Myrisk |
| Sun Pharmaceutical Industries INC. | $15.08 | 2025 | |
| Amgen INC. | $13.71 | 2023 | Blincyto, Kyprolis |
| Beone Medicines USA, INC. | $13.64 | 2025 | Brukinsa |
| Octapharma USA, INC. | $13.62 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Barr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.